COVAXIN for children: Bharat Biotech completes Phase 2/3 trials
Image Credit: shortpedia
Bharat Biotech has completed the Phase 2/3 trials of COVID-19 vaccine, COVAXIN for use in children under 18 years of age and is expected to submit the data by next week to the DCGI, Chairman, and Managing Director of Bharat Biotech International Ltd., Krishna Ella said. He said COVAXIN production would touch 55 million doses in October as against 35 million in September.